medigraphic.com
ISSN 0035-0052 (Print)

2021, Number 4

<< Back Next >>

Rev Mex Pediatr 2021; 88 (4)

Higher frequency of gene variants in the galactokinase gene in a series of cases from northern Mexico with galactosemia

López-Uriarte GA, Ortiz-Figueroa AC, Calvo-Anguiano G, Sánchez-Peña A, Torres-Sepúlveda MR, Lugo-Trampe JJ, Martínez-de VLE

Language: Spanish
References: 17
Page: 143-148
PDF size: 221.79 Kb.


ABSTRACT

Introduction: Galactosemia is an inborn error of galactose metabolism, caused by the deficiency of some of the enzymes GALT, GALK1, GALE and GALM. In this study, six cases with galactosemia and their clinical, biochemical and molecular characterization are presented. Material and methods: The clinical data of six patients with galactosemia are presented, as well as the nutritional treatment and follow-up are described. The diagnosis was made with an expanded neonatal screen. In patients with a total galactose measurement > 10 mg / dL, the Beutler test was performed. Molecular analysis for the GALT, GALE and GALK genes was performed by Sanger sequencing. Results: Three patients presented clinical data at the time of diagnosis, two with acute neonatal symptoms, the third with chronic symptomatology, reaching diagnosis at school age. The other three were asymptomatic. All six patients were offered nutritional treatment based on the elimination of galactose. In four patients, biallelic pathogenic variants were identified in GALK1 and one in GALT. In the sixth patient, a homozygous intronic deletion was detected in GALK1, classified as SNP. Conclusions: Galactosemia has a variable clinical spectrum, therefore, its diagnosis requires both its detection by metabolic screening and the identification of a compatible clinical picture. As part of the approach, the genetic aspect is essential in order to offer individualized genetic counseling.


REFERENCES

  1. Elsas LJ 2nd, Lai K. The molecular biology of galactosemia. Genet Med. 1998; 1(1): 40-48.

  2. Iwasawa S, Kikuchi A, Wada Y, Arai-Ichinoi N, Sakamoto O, Tamiya G et al. The prevalence of GALM mutations that cause galactosemia: A database of functionally evaluated variants. Mol Genet Metab. 2019; 126(4): 362-367.

  3. Calderon FR, Phansalkar AR, Crockett DK, Miller M, Mao R. Mutation database for the galactose-1-phosphate uridyltransferase (GALT) gene. Hum Mutat. 2007; 28(10): 939-943.

  4. Pyhtila BM, Shaw KA, Neumann SE, Fridovich-Keil JL. Newborn screening for galactosemia in the United States: looking back, looking around, and looking ahead. JIMD Rep. 2015;15:79-93. doi: 10.1007/8904_2014_302.

  5. Coss KP, Doran PP, Owoeye C, Codd MB, Hamid N, Mayne PD et al. Classical galactosaemia in Ireland: incidence, complications and outcomes of treatment. J Inherit Metab Dis. 2013; 36(1): 21-27.

  6. Torres-Sepúlveda MR, Martínez-de Villarreal LE, Esmer C, González-Alanís R, Ruiz-Herrera C, Sánchez-Peña A et al. Tamiz metabólico neonatal por espectrometría de masas en tándem: dos años de experiencia en Nuevo León, México. Salud Publica Mex. 2008; 50(3): 200-206.

  7. Tyfield L, Reichardt J, Fridovich-Keil J, Croke DT, Elsas LJ 2nd, Strobl W et al. Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Hum Mutat. 1999; 13(6): 417-430.

  8. Berry GT. Galactosemia: when is it a newborn screening emergency? Mol Genet Metab. 2012; 106(1): 7-11.

  9. Bosch AM, Bakker HD, van Gennip AH, van Kempen JV, Wanders RJ, Wijburg FA. Clinical features of galactokinase deficiency: a review of the literature. J Inherit Metab Dis. 2002; 25(8): 629-634.

  10. Schweitzer S, Shin Y, Jakobs C, Brodehl J. Long-term outcome in 134 patients with galactosaemia. Eur J Pediatr. 1993; 152(1): 36-43.

  11. Wilson JMG, Jungner G. Principles and practice of screening for disease [Internet]. Public Health Papers No 34. Geneva: World Health Organization; 1968.

  12. Kotb MA, Mansour L, William Shaker Basanti C, El Garf W, Ali GIZ, Mostafa El Sorogy ST et al. Pilot study of classic galactosemia: neurodevelopmental impact and other complications urge neonatal screening in Egypt. J Adv Res. 2018; 12: 39-45.

  13. Norma Técnica 321 para la Prevención del Retraso Mental producido por Hipotiroidismo Congénito [Internet]. México: Diario Oficial de la Federación, Órgano del Gobierno Constitucional de los Estados Unidos Mexicanos, Tomo CDXX; 1988. p. 89-90. [Acceso 22 de julio de 2020] Disponible en: http://www.dof.gob.mx/nota_detalle.php?codigo=4771733&fecha=22/09/1988

  14. Norma Oficial Mexicana NOM-034-SSA2-2013. Para la prevención y control de los defectos al nacimiento [Internet]. México: Diario Oficial de la Federación, Órgano del Gobierno Constitucional de los Estados Unidos Mexicanos, Tomo DCCXXIX, 24; 2014. [Acceso 22 de julio de 2020] Disponible en: https://www.dof.gob.mx/nota_detalle.php?codigo=5349816&fecha=24/06/2014

  15. Timson DJ. The molecular basis of galactosemia - Past, present and future. Gene. 2016; 589(2): 133-141.

  16. Coelho AI, Rubio-Gozalbo ME, Vicente JB, Rivera I. Sweet and sour: an update on classic galactosemia. J Inherit Metab Dis. 2017; 40(3): 325-342.

  17. Liu Y, Xia B, Gleason TJ, Castañeda U, He M, Berry GT et al. N- and O-linked glycosylation of total plasma glycoproteins in galactosemia. Mol Genet Metab. 2012; 106(4): 442-454.




2020     |     www.medigraphic.com